CSL and Alentis sign lixudebart partnership worth up to $1.555bn plus profit share
CSL and Alentis Therapeutics have entered a global lixudebart partnership worth up to $1.555 billion, with future profits shared between the companies.
CSL will pay $355 million initially and up to $1.2 billion in commercial milestones for the Phase II claudin-1 monoclonal antibody targeting rare kidney and liver diseases.
CSL will fund specified Phase II and Phase III development, while global profits will be split 55% to CSL and 45% to Alentis.
Field | Content |
Article Type | Deals |
Companies | CSL; Alentis Therapeutics |
Deal Type | Global co-development and co-commercialisation partnership |
Key Asset | Lixudebart |
Therapy Areas | Rare kidney disease; rare liver disease |
Technology/Modality | Claudin-1 monoclonal antibody |
Development Stage | Phase II |
Initial Payment | $355 million |
Potential Commercial Milestones | Up to $1.2 billion |
Potential Deal Value | Up to $1.555 billion |
Development Funding | CSL will fully fund specified Phase II and Phase III development |
Profit Share | 55% CSL; 45% Alentis |
What Happened | CSL and Alentis entered a global partnership to develop and commercialise lixudebart. |
Why It Matters | The agreement gives CSL access to a clinical-stage rare-disease programme while providing Alentis with substantial funding and a retained share of future economics. |
Supporting Context | Lixudebart targets claudin-1 and is being developed for serious rare kidney and liver diseases. |
Strategic Rationale | CSL is expanding its rare-disease pipeline while Alentis gains a global development and commercial partner for a lead clinical asset. |
Potential Impact | Successful development could create a new treatment approach for rare fibrotic kidney and liver conditions with limited therapeutic options. |
Key Takeaway | CSL and Alentis have partnered on lixudebart in a deal worth up to $1.555 billion plus a 55:45 profit share. |
What to Watch | Phase II results, transition into Phase III development and future regulatory strategy. |
Primary Source | CSL |
Relevant Date | 5 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments